Diagnosis and management of common chronic metabolic complications in HIV-infected patients

Postgraduate Medicine

Volumn 120, Issue 4, 2008, Pages 17-27

  Bader, Mazen S ^a   Kelly, Deborah V ^a  

^a MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

Author keywords

Diabetes mellitus; Dyslipidemia; Human immunodeficiency virus; Infectious disease; Insulin resistance; Lipodystrophy

Indexed keywords

ABACAVIR; ANTILIPEMIC AGENT; ANTIRETROVIRUS AGENT; ATAZANAVIR; ATORVASTATIN; BEZAFIBRATE; COLESTIPOL; COLESTYRAMINE; EFAVIRENZ; EZETIMIBE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METFORMIN; MEVINOLIN; NEVIRAPINE; PIOGLITAZONE; PRAVASTATIN; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; ROSIGLITAZONE; ROSUVASTATIN; SIMVASTATIN; STAVUDINE; SULFONYLUREA; TENOFOVIR; UNINDEXED DRUG;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; DIABETES MELLITUS; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG CONTRAINDICATION; DRUG SUBSTITUTION; DYSLIPIDEMIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERGLYCEMIA; HYPERTRIGLYCERIDEMIA; HYPOGLYCEMIA; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; LACTIC ACIDOSIS; LIFESTYLE MODIFICATION; LIPODYSTROPHY; METABOLIC DISORDER; MYOPATHY; OBESITY; PRACTICE GUIDELINE; PREVALENCE; REVIEW; RHABDOMYOLYSIS; SIDE EFFECT; TRIACYLGLYCEROL BLOOD LEVEL; METABOLISM;

ANTI-RETROVIRAL AGENTS; HIV INFECTIONS; HUMANS; METABOLIC DISEASES;

EID: 58149194016     PISSN: 00325481     EISSN: 19419260     Source Type: Journal    
DOI: 10.3810/pgm.2008.11.1930     Document Type: Review

References (59)

1. Lohse N, Hansen AB, Pedersen G, et al. Survival of persons with and without HIV infection in Denmark, 1995-2005. Ann Intern Med. 2007;146(2):87-95.
2. Bhaskaran K, Hamouda O, Sannes M, et al. CASCADE Collaboration. Changes in the risk of death after HIV seroconversion compared with mortality in the general population. JAMA. 2008;300(1):51-59.
3. Palella FJ Jr, Baker RK, Moorman AC, et al. Mortality in the highly active antiretroviral therapy era: Changing causes of death and disease in the HIV outpatient Study. J Acquir Immune Defic Syndr. 2006;43(1):27-34.
4. Morse CG, Kovacs JA. Metabolic and skeletal complications of HIV infection: the price of success. JAMA. 2006;296(7):844-854.
5. Jacobson DL, Tang AM, Spiegelman D, et al. Incidence of metabolic syndrome in a cohort of HIV-infected adults and prevalence relative to the US population (National Health and Nutrition Examination Survey), J Acquir Immune Defic Syndr. 2006;43(4):458-466.
6. Bennett MT, Johns KW, Bondy GP. Current and future treatments of HIV-associated dyslipidemia. Future Lipidol. 2008;3(2):175-188.
7. Shafran SD, Mashinter LD, Roberts SE. The effect of low-dose ritonavir monotherapy on fasting serum lipid concentrations. HIV Med. 2005;6(6):421-425.
8. Arribas JR, Pozniak AL, Gallant JE, et al. Tenofovir disopruzil fumarate, emtricitabine, and efavirenz compared with zidovudine, lamivudine and efacirenz in treatment-naive patients: 144-week analysis. J Acquir Immune Defic Syndr. 2008;47(1):74-78.
9. Gallant JE, Staszewski S, Pozniak AL, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naïve patients: a 3-year randomized trial. JAMA. 2004;282(2):191-201.
10. Sax PE. Strategies for management and treatment of dyslipidemia in HIV/AIDS. AIDS Care. 2006;18(2):149-157.
11. Van Leth F, Phanuphak P, Stroes E, et al. Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naïve patients infected with HIV-1. PLoS Med. 2004;1(1):e19.
12. Friis-Moller N, Sabin CA, Weber R, et al; Data Collection on Adverse Events of Anti-HIV Drugs (DAD) Study Group. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med. 2003;349(21):1993-2003.
13. Triant VA, Lee H, Hadigan C, Grinspoon SK. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J Clin Endocrinol Metab. 2007;92(7):2506-2512.
14. DAD Study Group; Friis-Møller N, Reiss P, Sabin CA, et al. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med. 2007;356(17):1723-1735.
15. Dubé MP, Stein JH, Aberg JA, et al; Adult AIDS Clinical Trials Group Cardiovascular Subcommittee; HIV Medical Association of the Infectious Disease Society of America. Guidelines Tor the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiviral therapy: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America and the Adults AIDS Clinical Trials Group. Clin Infect Disease. 2003;37(5):613-627.
16. Carosi G, Quiros-Roldan E, Torti C, et al. Members of the Italian Cardiovascular Risk Guidelines Working Group. First Italian consensus statement on diagnosis, prevention and treatment of cardiovascular complications in HIV-infected patients in the HAART era (2006). Infection. 2007;35(3):134-142.
17. Barrios A, Blanco F, García-Benayas T, et al. Effect of dietary intervention on highly active antiretroviral therapy-related dyslipemia. AIDS. 2002;16(15):2079-2081.
18. McPherson R, Frohlich J, Fodor G, Genest J. Canadian Cardiovascular Society: Canadian Cardiovascular Society position statement - recommendations for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease. Can J Cardiol. 2006;22(11):913-927.
19. American Diabetes Association. Standards of medical care in diabetes - 2008. Diabetes Care. 2008;31(suppl 1):S12-S54.
20. Nathan DM, Davidson MB, DeFronzo RA, et al. Impaired fasting glucose and impaired glucose tolerance: implications for care. Diabetes Care. 2007;30(3):753-759.
21. Brar I, Shuter J, Thomas A, Daniels E, Absalon J; Minorities and Women's Task Force of Terry Beirn Community Programs for Clinical Research on AIDS. A comparison of factors associated with prevalent diabetes mellitus among HIV-infected antiretroviral-naive individuals versus individuals in the National Health and Nutritional Examination Survey cohort. J Acquir Immune Defic Syndr. 2007;45(1):66-71.
22. Tien PC, Schneider MF, Cole SR, et al. Antiretroviral therapy exposure and incidence of diabetes mellitus in the women's Interagency HIV Study. AIDS. 2007;21(13):1739-1745.
23. Brown TT, Cole SR, Li X, et al. Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the multicenter AIDS cohort study. Arch Intern Med. 2005;165(10):1179-1184.
24. Howard AA, Floris-Moore M, Lo Y, Arnsten JH, Fleischer N, Klein RS. Abnormal glucose metabolism among older men with or at risk of HIV infection. HIV Med. 2006;7(6):389-396.
25. Meininger G, Hadigan C, Rielschel P, Grinspoon S. Body-composition measurements as predictors of glucose and insulin abnormalities in HIV-positive men. Am J Clin Nutr. 2002;76(2):460-465.
26. Johnson JA, Albu JB, Engelson ES, et al. Increased systemic and adipose tissue cytokines in patients with HIV-associated lipodystrophy. Am J Physiol Endocrinol Metab. 2004;286(2):E261-E271.
27. Jain MK, Aragaki C, Fischbach L, et al. Hepatitis C is associated with type 2 diabetes mellitus in HIV-infected persons without traditional risk factors. HIV Med. 2007;8(8):491-497.
28. Florescu D, Kotler DP. Insulin resistance, glucose intolerance and diabetes mellitus in HIV-infected patients. Antivir Ther. 2007;12(2):149-162.
29. Brinkman K, Smeitink JA, Romijn JA, Reiss P. Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy. Lancet. 1999;354(9184):1112-1115.
30. Morino K, Petersen KF, Dufour S, et al. Reduced mitochondrial density and increased IRS-1 serine phosphorylation in muscle of insulin-resistant offspring of type 2 diabetic parents. J Clin Invest. 2005;115(12):3587-3593.
31. Arner P. Insulin resistance in type 2 diabetes: role of fatty acids. Diabetes Metab Res Rev. 2002;18(suppl 2):S5-S9.
32. De Wit S, Sabin CA, Weber R, et al. Incidence and risk factors for new-onset diabetes in HIV-infected patients: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study. Diabetes Care. 2008;31(6):1224-1229.
33. Birkus G, Hájek M, Kramata P, Votruba I, Holý A, Otová B. Tenofovir diphosphate is a poor substrate and a weak inhibitor of rat DNA polymerases alpha, delta, and epsilon. Antimicrob Agents Chemother. 2002;46(5):1610-1613.
34. Shikuma CM, Yang Y, Glesby MJ, et al. Metabolic effects of protease inhibitor-sparing antiretroviral regimens given as initial treatment of HIV-1 Infection (AIDS Clinical Trials Group Study A5095). J Acquir Immune Defic Syndr. 2007;44(5):540-550.
35. Woerle HJ, Mariuz PR, Meyer C, et al. Mechanisms for the deterioration in glucose tolerance associated with HIV protease inhibitor regimens. Diabetes. 2003;52(4):918-925.
36. Moyle G. Metabolic issues associated with protease inhibitors. J Acquir Immune Defic Syndr. 2007;45(suppl 1):S19-S26.
37. Noor MA, Parker RA, O'Mara E, et al. The effects of HIV protease inhibitors atazanavir and lopinavir/ritonavir on insulin sensitivity in HIV-seronegative healthy adults. AIDS. 2004;18(16):2137-2144.
38. Aberg JA, Gallant JE, Anderson J, et al. HIV Medicine Association of the Infectious Diseases Society of America. Primary care guidelines for the management of persons infected with human immunodeficiency virus: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis. 2004;39(5):609-629.
39. Delahanty LM, Nathan DM. Implications of the diabetes prevention program and Look AHEAD clinical trials for lifestyle interventions. J Am Diet Assoc. 2008;108(4 suppl 1):S66-S72.
40. Garber A, Bergman D, Bloomgarden Z, et al. American College of Endocrinology consensus statement on the diagnosis and management of pre-diabetes in the continuum of hyperglycemia - when do the risks of diabetes begin? American Task Force on Diabetes. July 23, 2008. http://www.aace.com/ meetings/consensus/hyperglycemia/hyperglyce mia.pdf Accessed August 25, 2008.
41. Martinez E, Conget I, Lozano L, Casamitjana R, Gatell JM. Reversion of metabolic abnormalities after switching from HIV-1 protease inhibitors to nevirapine. AIDS. 1999;13(7):805-810.
42. Busti AJ, Bedimo R, Margolis DM, Hardin DS. Improvement in insulin sensitivity and dyslipidemia in protease inhibitor-treated adult male patients after switch to atazanavir/ritonavir. J Investig Med. 2008;56(2):539-544.
43. Walli RK, Michl GM, Bogner JR, Goebel FD. Improvement of HAART- associated insulin resistance and dyslipidemia after replacement of protease inhibitors with abacavir. Eur J Med Res. 2001;6(10):413-421.
44. Mulligan K, Yang Y, Wininger DA, et al. Effects of metformin and rosiglitazone in HIV-infected patients with hyperinsulinemia and elevated waist/hip ratio. AIDS. 2007;21(1):47-57.
45. Driscoll SD, Meininger GE, Ljungquist K, et al. Differential effects of metformin and exercise on muscle adiposity and metabolic indices in human immunodeficiency virus-infected patients. J Clin Endocrinol Metab. 2004;89(5):2171-2178.
46. Hadigan C, Yawetz S, Thomas A, Havers F, Sax PE, Grinspoon S. Metabolic effects of rosiglitazone in HIV lipodystrophy: a randomized, controlled trial. Ann Intern Med. 2004;140(10):786-794.
47. Slama L, Lanoy E, Valantin MA, et al. Effect of pioglitazone on HIV-1-related lipodystrophy: a randomized double-blind placebo- controlled trial (ANRS 113). Antivir Ther. 2008;13(1):67-76.
48. Hadigan C, Mazza S, Crum D, Grinspoon S. Rosiglitazone increases small dense low-density lipoprotein concentration and decreases high-density lipoprotein particle size in HIV-infected patients. AIDS. 2007;21(18):2543-2546.
49. Meier C, Kraenzlin ME, Bodmer M, Jick SS, Jick H, Meier CR. Use of thiazolidinediones and fracture risk. Arch Intern Med. 2008;168(8):820-825.
50. Singh S, Loke YK, Furberg CD. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA. 2007;298(10):1189-1195.
51. Nissen SE, Nicholls SJ, Wolski K, et al. PERISCOPE Investigators. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. JAMA. 2008;299(13):1561-1573.
52. Chow DC, Day LJ, Souza SA, Shikuma CM. Metabolic complications of HIV therapy. IAPAC Mon. 2006;12(9):302-317.
53. Fichtenbaum CJ, Hadigan CM, Kotler DP, et al. Treating morphologic and metabolic complications in HIV-infected patients on antiretroviral therapy. A consensus statement of an advisory committee of the International Association of Physicians in AIDS Care. IAPAC Mon. 2005;11(2):38-46.
54. Falutz J. Therapy insight: body-shape changes and metabolic complications associated with HIV and highly active antiretroviral therapy. Nat Clin Pract Endocrinol Metab. 2007;3(9):651-661.
55. Wierzbicki AS, Purdon SD, Hardman TC, Kulasegaram R, Peters BS. HIV lipodystrophy and its metabolic consequences: implications for clinical practice. Curr Med Res. 2008;24(3):609-624.
56. Waters L, Nelson M. Long-term complications of antiretroviral therapy: lipoatrophy. Int J Clin Pract. 2007;61(6):999-1014.
57. Samaras K. Metabolic consequences and therapeutic options in highly active antiretroviral therapy in human immunodeficiency virus-1 infection. J Antimicrob Chemother. 2008;61:238-245.
58. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. October 10, 2006:1-113. http://aidsinfo.nih.gov/contentfiles/AdultandAdolescentGL000629.pdf. Accessed August 22, 2008.
59. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. January 29, 2008:1-127. Available at: http://aidsinfo.nih.gov/contentfiles/ AdultandAdolescentGL.pdf. Accessed October 3, 2008.